EXPLORE!

Tegaserod approved for IBS with constipation in women with no heart disease

  1086 Views

#Gastroenterology  #Obstetrics and Gynecology 

eMediNexus    22 October 2018

The Gastrointestinal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted overwhelmingly (11 yes, 1 no) to recommend reintroducing tegaserod maleate (Zelnorm, Sloan Pharma) for the treatment of irritable bowel syndrome with constipation (IBS-C) in women without a history of cardiovascular (CV) ischemic disease and who have no more than one risk factor for CV disease.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.